PF 6480605

Drug Profile

PF 6480605

Alternative Names: PF-06480605

Latest Information Update: 09 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Biological factors
  • Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Phase I Crohn's disease

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 23 Sep 2016 Phase-II clinical trials in Ulcerative colitis (Treatment-experienced) in Poland (IV) (EudraCT2016-001158-16)
  • 08 Sep 2016 Phase-II clinical trials in Ulcerative colitis (Treatment-experienced) in USA (IV) (NCT02840721)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top